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Abstract
Despite recent therapeutic advances the prognosis of heart failure remains poor. Recent re-
search suggests that heart failure is a heterogeneous syndrome and that many patients
have stimulating auto-antibodies directed against the second extracellular loop of the β1 ad-
renergic receptor (β1EC2). In a human-analogous rat model such antibodies cause myocyte
damage and heart failure. Here we used this model to test a novel antibody-directed strate-
gy aiming to prevent and/or treat antibody-induced cardiomyopathy. To generate heart fail-
ure, we immunised n = 76/114 rats with a fusion protein containing the human β1EC2
(amino-acids 195–225) every 4 weeks; n = 38/114 rats were control-injected with 0.9%
NaCl. Intravenous application of a novel cyclic peptide mimicking β1EC2 (β1EC2-CP,
1.0 mg/kg every 4 weeks) or administration of the β1-blocker bisoprolol (15 mg/kg/day oral-
ly) was initiated either 6 weeks (cardiac function still normal, prevention-study, n = 24 (16
treated vs. 8 untreated)) or 8.5 months after the 1st immunisation (onset of cardiomyopathy,
therapy-study, n = 52 (40 treated vs. 12 untreated)); n = 8/52 rats from the therapy-study re-
ceived β1EC2-CP/bisoprolol co-treatment. We found that β1EC2-CP prevented and (alone
or as add-on drug) treated antibody-induced cardiac damage in the rat, and that its efficacy
was superior to mono-treatment with bisoprolol, a standard drug in heart failure. While biso-
prolol mono-therapy was able to stop disease-progression, β1EC2-CP mono-therapy -or as
an add-on to bisoprolol- almost fully reversed antibody-induced cardiac damage. The
cyclo¬peptide acted both by scavenging free anti-β1EC2-antibodies and by targeting
β1EC2-specific memory B-cells involved in antibody-production. Our model provides the
basis for the clinical translation of a novel double-acting therapeutic strategy that scavenges
harmful anti-β1EC2-antibodies and also selectively depletes memory B-cells involved in the
production of such antibodies. Treatment with immuno-modulating cyclopeptides alone or
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as an add-on to β1-blockade represents a promising new therapeutic option in immune-me-
diated heart failure.
Introduction
Heart failure (HF) is a major cause of hospitalization and death; overall 50% of the patients die
within four years of diagnosis [1]. HF may result from various causes and pathologies and is
therefore considered a heterogeneous syndrome rather than a single disease entity. The pres-
ence of auto-antibodies directed against the β1-adrenergic receptor (β1-AR) apparently identi-
fies a subgroup of patients at risk [2]. The β1-AR mediates most of the cardiac effects of the
catecholamines adrenaline and noradrenaline, which are often highly elevated and predict un-
favorable prognosis in HF [3,4]. Whereas short-term β1-AR stimulation improves cardiac per-
formance, its chronic activation leads to progressive deterioration of cardiac structure and
function [5].
During the past decade evidence has accumulated that many HF patients have functionally
active autoantibodies directed against and stimulating the cardiac β1-AR (anti-β1-abs) [6,7,8].
Such anti-β1-abs are found particularly in patients with idiopathic dilated cardiomyopathy
(DCM), which is characterised by dilatation and impaired contraction of the left or both ventri-
cles [9]. The presence of stimulating anti-β1-abs is associated with reduced cardiac function
[10], ventricular arrhythmias [2], sudden cardiac death [2,11], and increased cardiovascular
mortality [2]. This suggests a potential for strategies to counteract such harmful receptor-
antibodies.
Stimulating anti-β1-abs almost exclusively target the second extracellular loop of the β1-AR
(β1EC2), which is the largest and most structured of the three extracellular receptor loops and,
thus, may represent a readily accessible target on the cell surface [12,13]. Moreover, β1EC2 con-
tains T- and B-cell epitopes [14,15]. Recent data derived from the receptor’s crystal structure
underscore that β1EC2 is essential for the stabilisation and locking of the receptor’s agonist
binding pocket [13,16]. Thus, it seems conceivable that anti-β1EC2 may allosterically induce an
active state of the β1-AR [12,17]. Immunisation of Lewis rats against the β1EC2 gives rise to
stimulating anti-β1EC2, and within 8 months antibody-positive rats develop progressive cardi-
ac dilatation, wall-thinning, and loss of contractile function typical for DCM [18]. Isogenic
transfer of anti-β1EC2 to naїve Lewis rats likewise induced HF in recipients [6,18].
To target such harmful antibodies, we conceived a novel peptide-based strategy aiming to
specifically neutralise disease-inducing autoantibodies, in particular anti-β1EC2. In this aim we
generated peptide-homologs of β1EC2 and cyclised them to increase their stability in vivo [19]
and to better mimic the epitope-structure, and then investigated whether they might prevent
or have a therapeutic effect (alone or -to better mimic the clinical situation- as add-on to β1-
blocker therapy) in our rat model of anti-β1EC2-induced HF.
Materials and Methods
Generation and characterisation of β1EC2-cyclopeptides
Linear peptides comprising 24 amino-acids of the human β1EC2-sequence (AA199 to 222;
ARAESDEARRCYNDPKCCDFVTNRG)[20] were synthesised commercially on a Multiple
Peptide Synthesizer (SYROII, MultiSynTech GmbH, Witten, Germany) using the solid phase
Fmoc protocol with side chain protected Fmoc amino-acid derivatives on Rink Amide MBHA
resins (Novabiochem-Merck Biosciences GmbH, Bad Soden, Germany). For cyclisation of the
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peptide on the solid phase, an additional Fmoc-Glu-ODmab was incorporated at the C-termi-
nal end of the linear peptide; after selective removal of the Dmab side chain, the resin-bound
linear peptide was treated with diisopropyl-carbodiimide and N-hydroxy-9-azabenzotriazole
in N,N’-dimethyl-formamide for several hours. The cyclisation process was monitored by re-
peated Kaiser’-tests [59]. Cleavage from the synthesis resin generated a peptide amide; the pro-
tective groups of the cyclopeptide were removed by treating the resin with trifluoro-acetic acid/
triisopropylsilane/ ethandithiole/water for 2 hours. The generated cyclopeptide β1EC2-CP was
analysed by high pressure liquid chromatography (HPLC), and by mass spectrometry
(MALDI-MS).
A cyclic peptide corresponding to the β2EC2-sequence (comprising AA182 to 204; RATH-
QEAINCYANETCCDFFTNQG)[16] was synthesized and purified along the same lines and
served as a control for specificity.
Study-protocol and generation and characterisation of
anti-β1-EC2-antibodies
Fusion-proteins (FP) between glutathion-S-transferase (GST) and the 2nd extracellular loop of
the human β1-AR (β1EC2; AA195-225)[20] served as immunisation agent (β1EC2/GST-FP).
The study-protocol and guideline-conform animal housing conditions were approved by the
local authorities (Vote No. 621-2531.01-35/04, Experimental Animal Use and Care Committee,
Government of Lower Franconia, Bavaria, Germany).
In brief, n = 76 two months old Lewis/CrlBR rats were either s.c. immunised with 50 μg
β1EC2/GST-FP, or n = 38 rats were control-injected with 0.9% NaCl (t = 0). To maintain high
anti-β1EC2-titers, all immunised rats were boosted with β1EC2/GST-FP (or 0.9% NaCl) every
month over 20 months as previously described [18]. Application of the different linear or cyclic
β1-AR peptides (corresponding to the primary AA-sequence of either the first (β1EC1) or the
2nd extra-cellular β1-AR loop (β1EC2)) or the β1-receptor blocker bisoprolol was initiated either
6 weeks after the 1st immunisation (i.e. 15 days after the 1st boost, prevention-study), or 8.5
months after the 1st immunisation (therapy-study). At 4 week-intervals the animals received ei-
ther preventive (n = 24, treatment arms a, b, and f only) or therapeutic (n = 52, treatment
arms a-f) interventions over 12 months with (a) β1EC2-CP (1.0 mg/kg intravenously (i.v.)), (b)
bisoprolol (15 mg/kg/day orally, derived from titration pre-experiments [5/10/15mg] as oral dose
decreasing heart rate by at least 10%, e.g., 15mg: from 236±10 to 205±9 bpm; n = 5, p<0.005),
(c) β1EC2-Lin (1.0 mg/kg i.v.), (d) β1EC1-Lin (1.0 mg/kg i.v), (e) β1EC2-CP (1.0 mg/kg i.v.)
plus bisoprolol (15 mg/kg/day orally) co-treatment, or (f) no specific treatment (immunised
“positive”controls).
For treatment groups (a), (b), and (f) in total n = 38 non-immunised rats were injected with
0.9% NaCl and treated in parallel (“negative” controls). Blood was taken at regular intervals;
rat-IgG was prepared by caprylic acid precipitation and assayed for reactivity by ELISA or
competition-ELISA against linear peptides corresponding to the human β1EC2-sequence
(AA199-223)[12], and by immuno-fluorescence microscopy with human embryonic kidney
(HEK)293 cells stably expressing 0.4 pmol β1-AR/mg membrane protein (HEKβ1-cells) [18].
Specificity of the anti-β1EC2-abs was confirmed by co-localisation experiments using previous-
ly characterised N-terminal rabbit anti-β1-abs [21]. Bound antibodies were detected with ap-
propriate species-specific secondary antibodies (Dianova, Hamburg, Germany; anti-rabbit-, or
anti-rat-Fab2, conjugated to Cy2 or Cy3). Calibrated rat-IgG (Dianova) served to quantify spe-
cific IgG-antibodies.
The effects of anti-β1EC2 on β1AR-mediated intracellular cAMP-production were assessed
by measuring fluorescence resonance energy transfer (FRET) in HEKβ1-cells transiently
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transfected with a FRET-sensor for cAMP, Epac1-camps [8]. The sensor consists of the cAMP-
binding protein Epac1 flanked by enhanced cyan or yellow fluorescent protein. 48 h after trans-
fection with Epac1-camps, cAMP measurements were performed microscopically as described
[8]. The cells were maintained in FRET-buffer supplemented with 50 nM ICI 118551 (Sigma,
Deisenhofen, Germany) to block the small level of endogenous β2-AR (*0.1 pmol/mg mem-
brane protein). IgG-preparations were added to the cells at 0.13 μg/μl protein concentration;
2μM (-)isoproterenol (Sigma) was used as a reference to determine the maximal cAMP-re-
sponse. To test the blocking-efficacy of β1EC2-CP on anti-β1EC2-induced adrenergic signaling,
the different IgG-preparations were pre-incubated with β1EC2-CP (20 μg/μl) for 6 h at 4
°C; for
pharmacological blockade of anti-β1EC2-induced signals we utilised 5.0 μM bisoprolol.
Echocardiography and haemodynamic measurements
Echocardiograms were obtained from lightly anaestetised rats (30 mg/kg ketamine-HCl and
5 mg/kg xylazine i.p.) with a Vevo770 system (Visual Sonics Inc., Toronto, Canada) equipped
with a 17.5 MHz transducer as previously described [18], always by the same experienced echo-
cardiographer, who was blinded to the treatment groups. In brief, the rats were lightly anaeste-
tised (30 mg/kg ketamine-HCl and 5 mg/kg xylazine i.p.), shaved (chest), and placed supine on
a special table. M-mode tracings were recorded at baseline (before immunisation), and subse-
quently every four months in the parasternal long and short axis views according to the the
guidelines of the American Society for Echocardiography [22]. Pulsed-wave Doppler spectra
were recorded from the apical five-chamber view and the velocity-time integral (VTI) of the
transaortic flow served to calculate cardiac output (CO [ml/min] = Aortic VTI x (π [LV-
outflow tract diameter/2]2) x bpm). Reproducibility of the echocardiographic measurements
was assessed as previously described [18]; intra- and interobserver variabilities were<2%
or<5%.
Fourty-eight to 72 h after the final echo-Doppler examinations the rats underwent left heart
catheterisation using a 3.5 F high-fidelity catheter (Millar Instruments, Houston, Texas) as de-
scribed in [18]. LV-pressure tracings were recorded digitally over 15 min and analysed off-line
(PowerLab, A.D. Instruments, Castle Hill, Australia) [18].
Macroanatomy and histology of rat tissues
After further deep anesthesia (70 mg/kg sodium pentobarbital i.p.), the hearts were quickly re-
moved, rinsed with ice-cold relaxing-buffer (5% dextrose, 25 mM KCl in PBS), and weighed.
The apex was cut, frozen in isopentane (-56°C), and stored at -80°C for further analysis (bind-
ing and gene expression studies); the remainig tissue was fixed in 10% PBS-buffered formalin
(24–28 h). After the hearts all other relevant inner organs (e.g., lung, liver, spleen, kidneys,
brain, and eyes) were removed, rinsed with ice-cold PBS, weighed, sectioned, and fixed for fur-
ther histologic analysis.
Heart morphometry, histology, and TUNEL assay
From paraffin-embedded heart preparations cavity- and wall-dimensions were determined by
computer-aided analysis of H&E-stained mid-ventricular 2μm-sections as previously described
[18]. H&E-stained paraffin-sections also served to quantify damaged and fibrotic cardiac areas
(scars). For detection of mast cells, deparaffinised cardiac sections were stained with acidified
(pH<2.5) toluidine blue 0.1% (Sigma). The number of toluidine-positive cells was normalized
to square millimeter of cardiac tissue. TUNEL-positive cells were quantified in 2μmmid-
ventricular paraffin-sections using a TMR Red in Situ Death Detection Kit (Roche, Basel, Swit-
zerland). Only the total number of TUNEL-postive cells/section was determined without
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further differentiation of the specific apoptotic cell type (e.g., fibroblasts, endothelial cells,
cardiomyocytes).
Membrane preparation and radioligand binding studies
Membranes from apical cardiac tissues from rats of each study-group were prepared as previ-
ously described [18]. To determine total β-AR density (Bmax), 35μg membrane protein were in-
cubated (1.5 h, 25°C) in binding buffer with 200pM of the non-selective β-AR antagonist
125I-cyanopindolol (125I-CYP; Perkin Elmer Life and Analytical Sciences, Billerica, MA). Non-
specific binding was determined with 5μM unlabeled L-propranolol. The proportion of β1- and
β2-AR subtypes was estimated from biphasic competition-curves with 10
-10 to 10-2 M of the
unlabeled β1-selective antagonist CGP20712A (Sigma). The reaction was stopped by rapid fil-
tration (Whatman GF/C filters) and washing with ice-cold buffer. Filter-bound radioactivity
was measured by γ-counting. Estimates of maximal binding (Bmax) and the proportion of β1-
and β2-AR-subtypes were calculated with GraphPad Prism 5.00 (San Diego, CA).
Cardiac gene expression
Total RNA was isolated from frozen myocardium by RNeasy mini Kit (Qiagen, Hilden, Ger-
many). Reverse transcription of total RNA isolated from frozen myocardium was performed in
96-well plates utilising a high capacity RNA-to-cDNAmaster mix (Applied Biosystems, Foster
City, CA). PCR reactions were conducted in the presence of the fluorescent dye Sybr-Green
(Cambrex BioScience, East Rutherford, NY) and the reference-dye 6-carboxy-X-rhodamine
(ROX) using an ABI PRISM sequence detection system 7700 (Applied Biosystems). All ampli-
fication products were controlled for specificity by running a melting curve analysis; results
were calculated using the 2-ΔΔCT method. The relative expression levels were derived from a
standard curve and normalised to GAPDH as an endogenous control. Quantitative real-time
PCR (qRT-PCR) analyses are presented as fold change compared to untreated (0.9% NaCl-
injected) control hearts.
The primer-sequences were as follows (5’−3’): β1-AR sense: ATGGGTGTGTT-
CACGCTCTG, anti-sense: CAGCCAGTTGAAGAAGACGA; GRK2 sense: AGAGGGATGT-
CAATCGGAGA, anti-sense: AAGACCATCTGCCAGTCCAG; GRK5 sense:
ACCCTCCCTTCGTTCCAG, anti-sense: ACTTGGACCATACGGACGAT; IL1-β sense:
AAATGCCTCGTGCTGTCTG, anti-sense: TCGTTGCTTGTCTCTCCTTG; TGF-β1 sense
AAGAAGTCACCCGCGTGCTA, anti-sense: TGTGTGATGTCTTTGGTTTTGTCA.
Detection of antigen-specific CD4+ T-cells and memory B-cells as well
as antibody-secreting plasma cells, and plasmablasts
(a) Recall-assays with T-cells from spleens of immunised untreated vs. β1EC2-CP-treated ani-
mals were conducted as described in [60]. In brief, to purify CD4+ T-cells from the splenic cell
preparations, B-cells and CD8+ T-cells were depleted by commercially available magnetic
beads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany) yielding a purity>85%. 1x105
of the purified CD4+ T-cells were then co-incubated in 96-well plates with 1x106 irradiated thy-
mic antigen presenting cells (prepared from a younger rat). Reagents added in the different as-
says were 1.0 μg/ml β1EC2-CP, 1.0 μg/ml tuberculin purified protein derivative (PPD, internal
control), 1.0 μg/ml glutathion-S-transferase (GST), as well as 1.0 and 0.1 μg/ml GST/β1EC2-fu-
sion proteins (FP), respectively. Measured T-cell reactivities were normalised to medium. After
48 h of incubation the cells were pulsed with 1.25 μCi/well [3H]-thymidine and further incu-
bated for 16 h before the cells were harvested; the DNA-incorporated radioactivity was mea-
sured using a beta-plate counter.
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(b) For ELISPOT assays plates were coated overnight with either 1.8 μg/ml anti-rat IgG (H-
L) or the specific antigens (GST/β1EC2-FP or GST alone) in 50 mM Tris-buffer, pH 9.4. The
plates were then washed 3 times, blocked with BSA (3h, 37°C), and incubated overnight at
37°C with splenocytes or bone marrow cells from rats treated as indicated in RPMI 1640/X-
VIVO-15 medium supplemented with 10% FCS (1x103 to 106 cells per well). After 12 h the
cells were discarded and the plates were washed several times (PBS/0.5% Tween) before an al-
kaline phosphatase-conjugated secondary anti-rat-IgG antibody (0.3 μg/ml) was added to de-
tect bound rat IgG. After further incubation (3h, 37°C) and washing-steps (3 times PBS/0.5%
Tween) the plates were developed using LMP/BCIP 5:1 (1.0 ml per well; LMP, low melting aga-
rose; BCIP, 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt, a blue-colored dye).
(c) For flow cytometric detection of β1EC2-specific memory B-cells, splenocytes (1.5x10
8
cells per staining, 2x107 cells/ ml in PBS/0.1% BSA/0.02% NaN3) were first labelled with anti-
rat IgG(Fc) PE (Jackson Immunoresearch, West Grove, USA) followed by three washings and
a blocking step using normal rat serum plus GST (1:500 and 2 μg/ ml, respectively). After an-
other washing step, OX-33 FITC (BD, Heidelberg, Germany, 0.1 μg/ml) and DyLight649-la-
belled GST/β1EC2-FP (0.2 μg/ml) were added. All incubations were carried out for 15 min on
ice and in the dark. Finally, the cells were washed three times and analysed on a FACS-Calibur
(BD, Heidelberg, Germany) and FlowJo Software (Tree Star, Ashland, USA) was used to ana-
lyse the data.
(d) To detect functional β1EC2-specific memory B-cells in vivo, B-cells were first purified
from total splenocytes by negative depletion using mAb V65, R73, 10/78 andWT.5 plus mag-
netic beads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany) yielding average purities of
87%. 2.6x107 purified B cells were injected in 250 μl PBS i.v. into antigen-naïve syngeneic male
Lewis rats. To selectively trigger the transferred memory B-cells, recipient rats were immunised
after five days with only 12.5 μg GST/β1EC2-FP in adjuvans per animal. Serum was collected
for antibody detection just before as well as three and seven days after immunisation. Rats
without (memory) B-cell transfer did not produce anti-β1EC2 IgG within the seven-day obser-
vation period (data not shown).
Statistical analyses
Data are given as mean ±SEM of at least four animals per treatment-group if not otherwise
stated. Statistical analyses were performed using GraphPad Prism 5.00 (San Diego, CA). Func-
tional assays (FRET), molecular parameters (qRT-PCR), as well as haemodynamic and mor-
phometric parameters of antibody-positive vs. corresponding control rats or untreated vs.
treated animals, respectively, were analysed by Student’s t-test (where applicable) or repeated
measurements one-way ANOVA; significance between the different groups was analysed by
Dunnett’s post-test.
Kinetics of anti-β1EC2-antibodies and/or the different peptides (where applicable) and dif-
ferences between functional and echocardiographic parameters (long-term follow-up) were
analysed by two-way ANOVA followed by Bonferroni post-hoc testing. Values of p<0.05 were
considered statistically significant.
Results
Generation and neutralisation of stimulating anti-β1EC2-antibodies
To generate the anti-β1EC2-induced HF model, we immunised 68 male Lewis/CrlBR rats with
fusion-proteins (FP) containing glutathion-S-transferase (GST) and the human β1EC2
(amino-acids AA195-225)[20] every month in accordance with institutional guidelines as de-
scribed before [18]. All immunised rats developed high anti-β1EC2-titers (IgG-subclass, for all
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experiments prepared by caprylic acid precipitation), peaking 5–6 months after the
1st immunisation.
Specificity and conformational character of the resultant anti-β1EC2 towards β1-ARs was
ascertained along several lines: by larger ELISA signals with cyclic vs. linear β1EC2-peptides
(Fig. 1A), by a better recognition of cyclic vs. linear β1EC2-peptides in blocking assays (together
with a clear preference for β1- over β2-EC2 sequence (Fig. 1B)), and by a better concentration-
dependent neutralization in vitro achieved with cyclic vs. linear β1EC2-peptides (Fig. 1C). In
addition, immunofluorescence-studies confirmed that all rat anti-β1EC2 stained native human
β1-AR in the membrane of stably transfected human embryonic kidney cells (HEKβ1-cells),
and co-localised with purified β1-specific amino-terminal rabbit antibodies [21] (Fig. 1D). Fi-
nally, the anti-β1EC2 stimulated β1-AR-mediated signaling in HEKβ1-cells, as evidenced by an
increase in cAMP monitored with a co-transfected sensor that shows a decrease in fluorescence
resonance energy transfer (FRET) upon binding of cAMP [8]; these signals varied in amplitude
and in some cases almost reached the effects induced by the β-AR agonist isoproterenol
(Fig. 1E, right panel). No such cAMP-signals were detected with IgG prepared from 0.9%
NaCl-injected control rats (Fig. 1E, left panel). Also, control IgG reacted neither with β1EC2-
peptides in ELISA or competition assays (not shown), nor with β1-AR expressed in HEK-cells
(Fig. 1D). Stimulation of β1-AR/ cAMP signaling by anti-β1EC2 was inhibited by pre-incuba-
tion with β1EC2-peptides, again better by cyclic than by linear peptides (Fig. 1F, top panels); in-
terestingly, this inhibition was more efficient than that achieved by the specific β1-AR
antagonist bisoprolol (Fig. 1F, bottom right). As internal controls, we also generated cyclic
EC2-peptides of the β2-AR (β2EC2-CP). In ELISA, competition- and FRET-assays, anti-β1EC2
was not blocked at all by these β2-AR-derived peptides, documenting the β1-AR-specificity of
the generated antibodies (Fig. 1B and Fig. 1F, bottom left).
Cyclisation of the β1EC2-peptides not only improved recognition by the anti-β1EC2-anti-
bodies but, as predicted from studies on cyclotides from Viola odorata [19], also helped to
increase their stability in the circulation. Because plasma-half life in vivo as determined by 123I-
(tyrosine)-labeled β1EC2 linear (t ½ = 3.9±2.2 min) or cyclic β1EC2-peptides (t ½ = 8.1±2.8 min;
n.s.) in central venous blood samples (gamma-counted 2, 4, 6, 8, 10, 20, 30, and 60 min after in-
jection of 1.4 to 1.8 MBq 123I-labeled peptide/animal, not shown) merely reflected a compara-
ble instantaneous distribution of the respective radiolabeled peptides in the circulation—not
considering, e.g., extra-vascular accumulation and/or capillary redistribution (!)—we per-
formed additional ex vivo incubation experiments with whole blood to analyse differences in
peptide-stability strictly dependent on cyclisation. The latter experiments showed a significant-
ly longer half-life of β1EC2-CP (days) than that of its linear counterpart, β1EC2-Lin (hours), in-
ferring that cyclopeptides are more resistant to degradation by serum-peptidases than linear
peptides (Fig. 1G). Taken together, these data suggested that based on its specificity and longer
half-life in blood, the cyclopeptide β1EC2-CP might represent a promising drug candidate for
our immunisation-induced HF-model.
β1EC2-cyclopeptides prevent and reverse anti-β1EC2-induced heart
failure
The protocols of the two studies to either prevent or treat anti-β1EC2-induced HF are shown in
Fig. 2A and E. The rats were either immunised with β1EC2/GST-FP (n = 76) or control-in-
jected with 0.9%NaCl (n = 38), and boosted every month in order to maintain high anti-
β1EC2-titers. Application of the different peptides or bisoprolol was initiated either 6 weeks
after the 1st immunisation (i.e., 15 days after the 1st boost), when cardiac function was still fully
normal (called prevention-study, Fig. 2A), or 8.5 months after the 1st immunisation, at the
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Fig 1. Characterisation of stimulating rat anti-β1EC2. (A) ELISA-reactivity (mean±SEM) of n = 6 representative rat anti- β1EC2 (1:5000, 12h, 4°C) with
linear (dark green) or cyclic β1EC2-peptides (light green); p<0.005 (Student’s t-test). (B) Blocking capacity of linear β1EC2- or cyclic β1- and β2EC2 peptide-
homologues determined by competition-ELISA with linear β1EC2-peptides as antigen (AA199-223); columns are mean titers ±SEM. remaining in the sera
after preincubation (12h, 4°C) with a 40-fold excess of β1- or β2EC2-CP, or β1EC2-Lin (n = 20; **p<0.001, one way ANOVA and Dunnett’s post-hoc test). (C)
ELISA-competition experiments demonstrating the concentration-dependent blockade of rat anti- β1EC2 after preincubation with increasing amounts of
linear (squares) or cyclic β1EC2-peptides (diamonds); error bars indicate mean ±SEM of n = 3; *p<0.01; **p<0.001 (two way ANOVA and Bonferroni post-
hoc test). (D) Immunostaining experiments with rat anti- β1EC2 (1:100) using HEK-cells stably expressing β1-ARs (HEK β1) or not (wild type; HEKWT). IgG
was prepared from anti- β1EC2-positive rats or 0.9% NaCl-injected control rats. Amino-terminal β1AR-specific rabbit anti-bodies (1:250) served as positive
controls [21]. (E) Changes in cAMP levels in HEK β1-cells by rat anti- β1EC2. HEK β1-cells were transfected with the cAMP-sensor Epac1-camps [8], which
reacts to cAMP-binding with a reduction in fluorescence resonance energy transfer (FRET) between its fluorophores cyan (CFP) and yellow fluorescent
protein (YFP). Anti- β1EC2-induced activation of β1-AR causes increases in cytoplasmatic cAMP, resulting in a decrease in FRET. Representative FRET-
ratio traces of 1/8 experiments with rat anti- β1EC2 and control IgG are shown. (F) Blockade of anti-β1EC2-induced cAMP-signals after pre-incubation with
β1EC2-CP, β1EC2-Lin, β2EC2-CP (12h, 4°C) or 5.0μM bisoprolol. Representative FRET-ratio traces of 1/5 experiments are shown. Values are given in % of
maximal cAMP-response achieved with 0.3μM (-)isoproterenol (Iso). (G) Half-life of β1EC2-peptides in rat whole blood at room temperature. Rabbit anti-
β1EC2 served to determine the amount of intact peptides remaining after 2, 10, 30 min, 1, 2, 4, 8, 17, and 22 h by competition-ELISA with linear β1EC2-
peptides as antigen (duplicate experiments). Half-lifes derived from exponential curve fits were: β1EC2-CP, 486 h; β1EC2-Lin, 4 h.
doi:10.1371/journal.pone.0117589.g001
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Fig 2. Study protocol and cardioprotection with cyclic β1EC2-peptides. Flow charts of the (A) prevention- and (E) therapy-study with β1EC2-mimicking
peptides in the rat. Numbers given refer to animal-numbers in the respective study-groups. Immunisation with β1EC2/GST-FP (or 0.9% NaCl for controls)
was started at t = 0. Six weeks or 8.5 months after the 1st immunisation with β1EC2/GST-FP and onset of cardiomyopathy the rats received preventive or
therapeutic interventions with the indicated substances every 4 weeks over one year. Immunised untreated animals served as positive, 0.9% NaCl-injected
Cyclopeptide-Therapy in Immune Heart Failure
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time of cardiomyopathy onset (called therapy-study, Fig. 2E). The peptides (1.0 mg/kg) were
injected intravenously every four weeks, bisoprolol (15 mg/kg) was given orally every day
(drinking water), and untreated immunised animals received no specific intervention.
Due to the stringent immunisation procedure all rats rapidly developed high titers of anti-
β1EC2 peaking after 5–6 antigen-boosts, irrespective of bisoprolol-treatment (Fig. 2B and F).
In contrast, monthly preventive application of β1EC2-CPs from their very first injection on
abolished a further increase in anti-β1EC2-titers, and after 5 injections induced a>80% reduc-
tion in free anti-β1EC2-abs (vs. initial values, Fig. 2B). After 9–10 β1EC2-CP-injections, anti-
β1EC2-titers had decreased to barely 10% of the initial values despite monthly antigen-boosts
(Fig. 2B). In the therapy-study, the scavenger effect of β1EC2-CP was similar, yielding a pro-
gressive decline in anti-β1EC2-titers by>70% after two, and by>90% after 4–5 injections
(Fig. 2F), irrespective of bisoprolol co-treatment. After each injection, the acute scavenging-ef-
fect was visible; in addition, there was a sustained anti- β1EC2-decline despite monthly anti-
gen-boosts which resulted in steady state antibody-levels less than 15% of the titers at initiation
of therapy. In contrast, therapy with β1EC2-Lin produced only negligible effects, and injection
of β1EC1-Lin (S1 Fig.) or oral mono-treatment with bisoprolol (Fig. 2F, and S2B and S2F Fig.)
had no effect on anti- β1EC2-titers at all.
In both studies cardiac function was followed every 4 months by echocardiography, and
was assessed by left ventricular (LV) catheterisation at month 16 (prevention-study) or month
20 (therapy-study) as previously described.[18] After 8 months anti-β1EC2-positive untreated
rats developed LV-dilatation and -dysfunction that progressed continuously in the course of
both studies. In the prevention-study, echocardiography and cardiac catheterisation (Fig. 2C
and D, and S2 Fig.: A, C, E and G) as well as histomorphology of the hearts (Table 1) of un-
treated vs. treated animals revealed that both bisoprolol and β1EC2-CP were able to prevent de-
velopment of cardiomyopathy and heart failure.
In the therapy-study, β1EC2-CP (injected either alone or as add-on to bisoprolol-treatment)
almost fully reversed the cardiomyopathic phenotype that had developed before the initiation
of therapy, whereas mono-therapy with bisoprolol only stopped further disease-progression.
With β1EC2-CP (alone or as add-on), echocardiographic LV-dimensions, LV-ejection fraction
and cardiac index (Fig. 2G), LV end-diastolic pressure and systolic contraction (Fig. 2H) as
well as the heart weight of cardiomyopathic rats returned to control values (Table 2). In con-
trast, β1EC1-Lin or β1EC2-Lin failed to elicit any cardiopotective effects (S2 Fig.: B, D, and F).
Unlike bisoprolol (alone or as add-on), neither linear peptides nor β1EC2-CP decreased heart
rate or blood pressure of treated animals (S2 Fig.: G and H).
Morphometry and immunohistology of midventricular 2μm-sections of the hearts ana-
lysed at the end of the therapy-study underscored the beneficial effects of β1EC2-CP (alone or
as add-on). The number of myocardial fibrotic scars (Fig. 3A and B) and TUNEL-positive
apopotic cells (Fig. 3C) returned to normal levels in β1EC2-CP-treated rats. Such a reversal
was not seen with bisoprolol mono-therapy (Fig. 3A-C). By contrast, the increases in cardiac
transcripts of distinct profibrotic markers (IL1-β, TGF-β1) observed in immunisation-
rats as negative controls. Time-course of anti-β1EC2-titers in the (B) prevention- and (F) therapy-study. Titers were measured before and 24h after CP-
injection. Values in (B) correspond to the anti-β1EC2-titers in mg/ml over 16 study-months (black circles, untreated; diamonds, β1EC2–CP (1.0 mg/kg/month
i.v.); triangles, bisoprolol (15 mg/kg/day orally)). Values in (F) correspond to the anti-β1EC2-titers in mg/ml over 20 study-months (black circles, untreated;
green diamonds, β1EC2-CPmono-treated; blue triangles, bisoprolol mono-treated; purple diamonds, β1EC2-CP/bisoprolol co-treated). For better readability
error-bars are not shown in the graph. Echocardiography in the (C) prevention- and (G) therapy-study. Graphs show the time-course of the LV end-diastolic
diameter (LVED). Lower panels: Time-course of the cardiac index derived from cardiac output/ body weight. Error bars indicate mean ±SEM in the indicated
groups; *p<0.01; **p<0.001 (two way ANOVA and Bonferroni post-hoc test). Invasively obtained parameters in the (D) prevention- and (H) therapy-study.
Upper panels show LV end-diastolic pressures (mmHg), lower panels contractilility (+dP/dt, mmHg/s). Error bars indicate mean ±SEM of the indicated
groups; ns, not significant; *p<0.01; **p<0.001 (one way ANOVA and Dunnett`s post-hoc test).
doi:10.1371/journal.pone.0117589.g002
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induced HF were reduced by*50% with either β1EC2-CP or bisoprolol mono-treatment,
and even by >70% in the co-treatment group (indicating an synergistic anti-inflammatory
effect, Fig. 3D). Also the documented increase in cardiac mast cells in immunized rats was re-
versed to control levels by both substances (either as mono- or as co-treatment, Fig. 3E). Fur-
ther morphometric analysis of the hearts revealed enlarged LV-cavities and wall thinning in
untreated cardiomyopathic rats. All these features, including the heart weight, were returned
to normal in β1EC2-CP-treated animals (Table 2 and Table 3). Moreover, the relative wet
weight (Table 2), histology (S3 Fig.), and selected laboratory parameters (S4 Fig.) of other or-
gans than the heart revealed an increase in lung and liver weight in untreated anti-β1EC2-
positive rats (accompanied by a significant increase in GLDH). These signs of congestion
were almost reverted in β1EC2-CP-treated, but not in bisoprolol mono-treated animals. Im-
portantly, no β1EC2-CP-related pathologies were noted in treated vs. control animals. In par-
ticular, neither the kidneys nor other inner organs, nor the eyes of β1EC2-CP-treated rats
had any signs of damage or organ-toxicity attributable to an accumulation or deposition of
anti-β1EC2/β1EC2-CP-complexes (S3 Fig.).
Cardiac failure is usually accompanied by downregulation of cardiac β1- but not β2-ARs,
and by upregulation of cardiac GRKs [4,23,24]. Radioligand-binding studies with 125I-cyano-
pindolol and selective antagonists showed that β1-specific downregulation of β-ARs also oc-
curred in our immunisation-induced HF-model [18], and that this downregulation was largely
prevented by (mono-)application of β1EC2-CP alone (Fig. 4A and B). As typical for a β-AR an-
tagonist, bisoprolol (mono-)treatment even induced a small increase in cardiac β1-ARs, an
Table 1. Macroanatomy and haemodynamic parameters (prevention-study).
Control Cont./biso. Cont./EC2-CP β1 immun. β1 immun. /biso. β1 immun. /EC2-CP
Heart, mg/g 2.55 ±0.03 2.50 ±0.06 2.50 ±0.06 2.78 ±0.04* 2.55 ±0.06 2.46 ±0.05
Spleen. mg/g 1.72 ±0.15 1.79 ±0.05 1.58 ±0.15 1.63 ±0.08 1.74 ±0.05 1.48 ±0.05
Kidney R, mg/g 2.89 ±0.07 2.90 ±0.07 2.79 ±0.01 2.78 ±0.08 2.73 ±0.07 2.79 ±0.06
Kidney L, mg/g 2.74 ±0.10 2.79 ±0.05 2.62 ±0.08 2.68 ±0.14 2.63 ±0.04 2.71 ±0.08
Lung, mg/g 2.86 ±0.09 2.66 ±0.22 2.77 ±0.10 2.89 ±0.12 2.74 ±0.07 2.74 ±0.14
Liver, mg/g 21.18±0.98 22.33 ±0.78 22.51±0.20 24.71±0.98† 22.63±0.46 23.59±0.46
Weight, g. 580 ±31 546 ±8 553 ±11 562 ±4 533 ±27 543 ±24
HF, bpm 246 ±10 173 ±17‡ 232 ±7 217 ±4 178 ±9‡ 226 ±5
LVSP, mmHg 133 ±6 107 ±11* 135 ±7 119 ±1 106 ±3† 127 ±4
LVEDP, mmHg 9.9 ±1.0 10.6 ±1.5 10.1 ±1.4 14.8 ±0.4‡ 8.3 ±0.6 10.4 ±0.6
+dP/dt, mmHg/s 7667 ±130 7012 ±419 7217 ±83 6028 ±23‡ 6768 ±106† 7254 ±118
-dP/dt, mmHg/s 6021 ±160 5619 ±155 5986 ±288 5067 ±76‡ 5532 ±78* 5887 ±93
The upper part of the table shows the relative (wet) weights in g/kg body weight of selected organs in the groups of the prevention-study. Non-immunised
0.9% NaCl-injected rats had no intervention (Control) or received treatment with either bisoprolol (Cont./biso.) or β1EC2-CP (Cont./EC2-CP). Similarly,
immunised anti-β1EC2-positive rats had either no intervention (β1-immun.) or received bisoprolol (β1-immun./biso.) or β1EC2-CP (β1-immun./EC2-CP).
Values given are mean weights ±SEM of heart, spleen, kidneys (R, right; L, left), lung, and liver, respectively. The lower part of the table shows invasively
obtained haemodynamic parameters in the prevention-study. Parameters given are (from top to bottom, mean ±SEM): body weight (g), heart frequence
(bpm), maximal systolic LV-pressure (mmHg), LV end-diastolic pressure (mmHg), contractilility (+dP/dt, mmHg/s), and relaxation (-dP/dt, -mmHg/s). One
way ANOVA and Dunnett`s post-hoc test
Treated vs. control
*p<0.05
†p<0.01
‡p<0.001.
doi:10.1371/journal.pone.0117589.t001
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effect that was fully preserved with β1EC2-CP/bisoprolol co-treatment (Fig. 4B). No changes
were seen for β2-AR under any of the study conditions. Corresponding to the downregulation
of cardiac β1-AR protein, β1-AR mRNA-levels were also significantly reduced in untreated car-
diomyopathic rats and returned to normal levels with either β1EC2-CP or bisoprolol treatment
alone or with β1EC2-CP/bisoprolol combination-therapy (Fig. 4C). Moreover, qPCR-analysis
of the expression of G protein-coupled receptor kinases (GRKs) involved in counter-balancing
sympathetic activity [4,24,25] revealed an upregulation of GRK2 and GRK5 in immunisation-
induced HF, which was reverted by bothβ1EC2-CP and (to a somewhat lesser extent) by biso-
prolol mono-therapy (Fig. 4C), whereas co-treatment with both substances had a clear syner-
gistic effect, resulting even in a slight (non-significant) down-regulation of both GRK’s
(Fig. 4C).
Table 2. Macroanatomy and haemodynamic parameters (therapy-study).
Control Cont./
biso.
Cont./
EC2-CP
β1
immun.
β1 immun.
/biso.
β1 immun.
/EC2-CP
β1 immun.
/EC2-Lin.
β1 immun.
EC1-Lin.
β1 immun. EC2-
CP + biso.
Heart, mg/g 2.10 ±
0.04
2.27
±0.09
2.15 ±0.08 3.18
±0.22‡
2.93 ±0.11† 2.20 ±0.09 2.88 ±0.24* 2.91 ±0.12* 2.37 ±0.08
Spleen, mg/
g
1.31 ±
0.08
1.54
±0.05
1.18 ±0.03 1.50 ±0.08 1.69 ±0.07 1.23 ±0.04 1.49 ±0.09 1.27 ±0.09 1.62 ±0.07
Kidney R,
mg/g
2.34 ±
0.10
2.18
±0.09
2.22 ±0.08 2.47 ±0.13 2.57 ±0.10 2.25 ±0.05 2.36 ±0.20 2.23 ±0.08 2.37 ±0.07
Kidney L,
mg/g
2.28 ±
0.07
2.19
±0.07
2.19 ±0.08 2.42 ±0.12 2.54 ±0.07 2.29 ±0.06 2.32 ±0.14 2.36 ±0.07 2.27 ±0.06
Lung, mg/g 2.16 ±
0.15
2.07
±0.06
2.08 ±0.07 2.96
±0.09‡
2.88 ±0.10* 2.26 ±0.16 2.77 ±0.12* 2.98 ±0.09† 2.35 ±0.08
Liver, mg/g 19.1 ±
0.70
18.5
±0.55
18.9 ±0.55 22.95
±0.71†
21.61 ±1.47* 19.83 ±0.50 22.64 ±0.59* 22.89 ±0.41* 20.19 ±0.66
Weight, g 710 ±26 613 ±
22†
695 ±27 648 ±22 598 ±13 673 ±12 598 ±38 689 ±21 606 ±16
HF, bpm 221 ±3 168 ± 6‡ 221 ±7 214 ±4 173 ± 3‡ 217 ±3 210 ±6 217 ±6 182 ± 2‡
LVSP,
mmHg
125 ±6 104 ± 4* 121 ±8 106 ± 3* 108 ± 2* 126 ±4 116 ±4 104 ± 3* 108 ± 3*
LVEDP,
mmHg
7.8 ±0.8 9.7 ± 0.9 9.2 ± 1.1 15.8 ±
0.8‡
10.9 ± 1.3 10.0 ± 1.0 14.5 ±1.2† 13.8 ±0.6* 10.0 ± 0.6
+dP/dt,
mmHg/s
6979
±173
6018
±308
6566 ±416 5249 ±
225‡
5697 ± 231† 6559 ±190 5902 ±171* 5146 ±384‡ 6238 ±193
-dP/dt,
mmHg/s
5765
±309
4646 ±
295†
5502 ±248 4079 ±
159‡
4238 ± 117‡ 5228 ±166 4857 ±157* 3996 ±106‡ 4991 ±106
The upper part of the table shows the relative (wet) weights in g/kg body weight of selected organs in the groups of the therapy-study. Non-immunised
0.9% NaCl-injected rats had no intervention (Control) or received treatment with either bisoprolol (Cont./biso.) or β1EC2-CP i.v. (Cont./EC2-CP).
Similarly, immunised anti-β1EC2-positive rats remained either untreated (β1-immun.) or were treated with (oral) bisoprolol (β1-immun./biso.) or i.v.-
injected with β1EC2-CP, β1EC2-Lin, or β1EC1-Lin (β1-immun./EC2-CP/ EC2-Lin/ EC1-Lin), or received β1EC2-CP/bisoprolol co-treatment (β1-immun./
EC2-CP+biso.). Values given are mean weights ±SEM of heart, spleen, kidneys (R, right; L, left), lung, and liver, respectively. The lower part of the table
shows invasively obtained haemodynamic parameters in the therapy-study. Parameters given are (from top to bottom, mean ±SEM): body weight (g),
heart frequence (bpm), maximal systolic LV-pressure (mmHg), LV end-diastolic pressure (mmHg), contractilility (+dP/dt, mmHg/s), and relaxation (-dP/dt,
-mmHg/s). One way ANOVA and Dunnett`s post-hoc test
Treated vs. control
*p<0.05
†p<0.01
‡p<0.001.
doi:10.1371/journal.pone.0117589.t002
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Immunomodulating effects of β1-EC2-cyclopeptides
To assess whether preventive and/or therapeutic treatment of anti-β1EC2-positive rats with the
different peptides interfered with the immunopathology of antibody-induced HF, we deter-
mined the kinetics of anti-β1EC2-abs before and 24 h after peptide-application by ELISA (mea-
suring only free anti-β1EC2-abs). In immunised untreated animals, anti-β1EC2-titers
continuously increased after each antigen-boost (Fig. 2B and F). In line with an antibody-scav-
enging effect, treatment with β1EC2-CP already after two injections significantly decreased,
and after 5 injections almost fully suppressed a rise in free anti-β1EC2, while bisoprolol
Fig 3. Histology of rat hearts (therapy-study). (A) Representative H&E-stained 2μm cross-sections of hearts (from the left to the right) from a control rat, an
immunised untreated rat, a bisoprolol- and a β1EC2-CPmono-treated rat, and a β1EC2-CP/bisoprolol co-treated rat. (B)Quantification of fibrotic scars in
midventricular 2μm-sections (mvhs, mid-ventricular heart-section). Columns ± error bars represent the mean number of fibrotic scars ±SEM per 3 heart
sections in the indicated groups. (C) TUNEL-assay with 2μm-mvhs. Columns ± error bars represent mean numbers ±SEM of apoptotic cells (kind of cells not
specified) /3 mvhs. (D) qRT-PCR of apical cardiac tissues. Columns ± error bars represent the expression of the indicated pro-fibrotic markers ±SEM in the
indicated treatment-groups normalised to controls. (E)Mast cells in 2μm paraffin-mvhs from the indicated treatment-groups; columns ± error bars represent
the mean numbers ±SEM of mast cells/mm2 cardiac tissue. For all parameters shown, differences between the treatment-groups were assessed by repeated
measures one way ANOVA and Dunnett`s post-hoc test; *p<0.05; **p<0.001.
doi:10.1371/journal.pone.0117589.g003
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treatment did not affect the amount of free anti-β1EC2-abs. With preventive and also with (re-
peated) therapeutic application of β1EC2-CP, anti-β1EC2-levels remained low despite contin-
ued boosting with β1EC2/GST-FPs (Fig. 2B and F). This unexpected titer-course, monitored
more closely in the first 6 months of the prevention-study (Fig. 5A), suggested that beside its
action as a simple scavenger, β1EC2-CP also negatively impacted on B- and/or T-cells as the
lymphocyte populations responsible for anti-β1EC2-production. Moreover, as even preventive
injection was initiated after the priming-immunisation and production of class-switched anti-
β1EC2 of the IgG isotype, β1EC2-CP-treatment putatively interfered with the function not of
naïve, but of already differentiated memory B-cells, plasma cells (PC), and/or T-cells.
For T-cells, treatment with antigenic peptides has been shown to either induce dominant
unresponsiveness of the CD4+ T cell-compartment via induction of CD4+CD25+ regulatory
T-cells (Treg cells)[26] or to functionally impair non-Treg CD4
+ T helper cells [27]. We, there-
fore, tested the in vitro recall responses of purified CD4+ T-cells isolated from the spleens of
preventively (Fig. 5B and C) or therapeutically (Fig. 5D) treated and untreated rats to the
β1EC2/GST-FP and its components. CD4
+ T-cells from both groups clearly responded to the
FP but not to β1EC2-CP, indicating that the relevant CD4
+ T-cell epitopes were contained
within GST (Fig. 5B-D). Further in vitro testing did also not provide any evidence for an in-
duction of β1EC2-specific Treg cells by β1EC2-CP in vivo (not shown).
As the T cell-compartment appeared not to be targeted by β1EC2-CP we further analysed
the cells directly involved in antibody-production, i.e. B-cells and PC. ELISPOT assays using
splenocytes or bone marrow cells freshly isolated from rats two weeks after the last antigen-
boost allowed us to determine the frequencies of (mostly) long-lived PC in these organs; how-
ever, these experiments revealed that β1EC2-CP-treatment did not reduce the frequencies of
anti-β1EC2-producing PC (Fig. 5E and F).
While long-lived PC express very little or no immunoglobulins on the cell surface [28], B-
cells do and could thus serve as direct targets of β1EC2-CPs. To detect the few antigen-
Table 3. Morphometric analysis of rat hearts (therapy-study).
Control Cont./
biso.
Cont./
EC2-CP
β1
immun.
β1 immun.
/biso.
β1 immun.
/EC2-CP
β1 immun.
/EC2-Lin.
β1 immun.
EC1-Lin.
β1 immun. EC2-
CP + biso.
LVA, mm2 59.9
±1.8
58.4
±0.7
57.4 ±0.7 68.3
±0.8*
61.9 ±5.2 65.2 ±2.5 71.2 ±3.5† 70.9 ±1.4* 55.4 ±1.7
LVCA,
mm2
24.1
±0.9
22.6
±0.2
21.3 ±0.1 31.1
±0.3‡
26.8 ±1.0 25.6 ±1.0 32.7 ±1.3‡ 32.4 ±1.5‡ 22.5 ±1.5
LVWA,
mm2
36.9
±1.3
35.8
±0.5
36.1 ±0.7 37.2 ±0.7 35.0 ±4.5 39.6 ±1.7 38.5 ±2.4 38.5 ±0.8 34.8 ±1.6
LVCA /
LVA %
39.6
±0.8
38.7
±0.5
37.2 ±0.5 45.6
±0.6‡
43,9 ±0.8† 39.4 ±0.8 46.1 ±0.9‡ 45.6 ±1.4‡ 37.1 ±1.2
IVS, mm 1.7 ±0.1 1.8 ±0.1 1.7 ±0.1 1.5 ±0.1* 1.7 ±0.1 1.7 ±0.1 1.5 ±0.1* 1.4 ±0.1* 1.6 ±0.2
PW, mm 1.8 ±0.1 1.8 ±0.1 1.9 ±0.1 1.6 ±0.1* 1.5 ±0.1 1.8 ±0.1 1.6 ±0.1* 1.6 ±0.1* 1.7 ±0.1*
Morphometric data of rat hearts harvested at the end of the therapy-study were obtained by computer-aided analysis of H&E-stained mid-ventricular 2 μm
cross-sections as previously described in detail [18]. Parameters given are (from top to bottom, mean ±SEM): LVAtot, total LV-area; LVCA, LV-cavity area;
LVWA, LV wall area (including LVCA/LVWA-ratio in %); IVS, thickness of the inter-ventricular septum; PW, posterior wall thickness (one way ANOVA and
Dunnett`s post-hoc test
Treated vs. control
*p<0.05
†p<0.01
‡p<0.001.
doi:10.1371/journal.pone.0117589.t003
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specific memory B-cells within splenocytes of treated vs. untreated rats we differentiated
memory B-cells into short-lived plasmablasts by boosting the rats with β1EC2/GST-FPs three
days prior to the analysis [29]. This allowed us to detect them together with long-lived PC by
ELISPOT.
Preventive (Fig. 5G and H) as well as therapeutic (Fig. 5I and J) application of β1EC2-CPs
resulted in a*80% reduction in the frequencies of splenocytes secreting anti-β1EC2-abs,
which was not achieved with β1EC2-Lin (S5A Fig.). As long-lived PC were not targeted by
β1EC2-CPs (Fig. 5E), this means that more than 80% of the β1EC2-specific memory B-cells
were affected by this kind of treatment impairing B-cell receptor (BCR)-mediated β1EC2-
specific memory B-cell expansion and differentiation into anti-β1EC2-producing PC. Direct
detection of β1EC2-specific memory B-cells by flow cytometry (Fig. 5K and L) further re-
vealed complete depletion of this cell population by β1EC2-CP treatment. Accordingly,
transfer of purified B-cells from immunised β1EC2-treated rats into antigen-naïve recipients
followed by suboptimal immunisation with β1EC2/GST-FP (12.5μg instead of 50μg in
Fig 4. Cardiac adrenergic system andmolecular markers. Columns represent the relative amount of β1/β2-AR subtypes (fmol/mg protein) in cardiac
membranes of anti-β1EC2-positive immunised rats (A) preventively or (B) therapeutically treated with either bisoprolol or β1EC2-CP alone, or with a
combination of both, and corresponding control animals (prevention-arm, month 16; therapy-arm, month 20). Error bars indicate mean values ±SEM of the
indicated treatment groups; *p<0.05. (C) Molecular analysis of hearts (apical segments) from treated anti-β1EC2-positive rats and corresponding control
animals in the therapy-study. Columns ± error bars represent the level of expression of the indicated markers ±SEM in cardiac tissues from the indicated
treatment-groups compared to values from 0.9% NaCl-injected rats (controls, set at 100%), as determined by qRT-PCR normalised to GAPDH (one way
ANOVA and Dunnett`s post-hoc test; *p<0.05; **p<0.001).
doi:10.1371/journal.pone.0117589.g004
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adjuvans) did not induce detectable amounts of anti-β1EC2-abs in the serum of the recipient
rats while B-cells from immunised untreated rats did (Fig. 5M). In summary, our results sug-
gest that β1EC2-CP protects rats from immunisation-induced HF, both, by specifically scav-
enging free anti-β1EC2 and by depleting β1EC2-specific memory B-cells. It should be noted,
however, that the overall numbers of IgG-producing cells were not at all affected by β1EC2-
CP-treatment (Fig. 5F, H, and J), precluding a general immuno-suppressant effect of the
cyclic peptide.
Discussion
Autoantibody-induced diseases and current treatment approaches
Autoantibodies directed against self-antigens are the hallmark of many autoimmune diseases,
and some of them may even directly cause the disease [30,31]. In Graves‘disease [32], myasthe-
nia gravis [33], and a sub-entity of insulin-resistant diabetes [30] functional autoantibodies
(abs) directed against membrane receptors have been recognised as main pathogenetic factors.
This illustrates that receptors, proteins that are generally considered as not very immunogenic,
can serve as targets for disease-causing abs. This appears to be the case also in a significant
number of HF patients, where anti-β1AR-abs are suspected to contribute to the development of
DCM [2,6,7,8,10,11,18,34,35,36].
Current treatment approaches in autoantibody-induced diseases comprise either targeting
the abs themselves, as is the case for immunoadsorption [36], or the cells producing the abs, i.e.
short-lived plasmablasts and/or long-lived plasma cells. While plasmablasts and their precur-
sors, i.e. memory B-cells, may be deleted by cytostatic drugs like cyclophosphamide [37] or
anti-CD20+-abs [38], ablation of long-lived plasma cells requires the use of proteasome-inhibi-
tors [39]. All these therapies present specific problems in terms of unwanted effects and out-
come; in particular, proteasome-inhibitors are quite cardiotoxic, rendering them not suitable
for the treatment of anti-β1AR-mediated HF [40].
Here we present a novel approach to address such disease-causing abs based on cyclic
peptides mimicking the relevant target-epitope. We and others have previously shown that
immunisation against the 2nd extracellular loop of the β1-AR gives rise to receptor-stimulating
anti-β1EC2 in various animal models [12,14,18,35,41]. Such antibodies appear to allosterically
activate the receptors and their signaling cascade, and this activation occurs both in the absence
and in the presence of catecholamines [6,12,18]. In the long run, such anti-β1EC2 cause myo-
cardial tissue injury, characterised by myocyte apoptosis and fibrosis, myocyte dysfunction,
cardiac dilatation, and in the end congestive HF [5,6]. The most likely explanation is that
Fig 5. Immunology of cyclic β1EC2-peptides: fate of β1EC2-specific T- and B-cells. (A) Titer-course of anti-β1EC2-abs in β1EC2-CP-treated rats during
the first 6 months of the prevention-study before and 24h after cyclopeptide-injection. Time-points of antigen-boosts are indicated by (red) lines, time-points
of CP-injections by (green) arrows. For better readability error-bars are not shown in the graph. (B) Pre-experiments (antigenic recall-assays) performed with
CD4+ T-cells prepared from spleens of GST/β1EC2 fusion-protein (FP)-immunised untreated (n = 3, black) vs. 0.9%NaCl-injected control rats (n = 3, white).
(C andD) Reactivities of CD4+ T-cells prepared from (C) preventively or (D) therapeutically β1EC2-CP- (green) or bisoprolol-treated animals (blue) compared
to cells prepared from immunised untreated (black) or corresponding 0.9%NaCl-injected control rats (white). Columns ± error bars represent mean T-cell
reactivities ±SEM normalized to medium (abbreviations: EC2-CP, cyclopeptide mimicking β1EC2; GST, glutathion-S-transferase; PPD, purified protein
derivative; FP, GST/β1EC2 fusion-protein). (E and F) ELISPOT-assays to detect long-lived plasma cells (PC) in bone marrow (BM) and spleens of untreated
(black, n = 4) vs. β1EC2-CP-treated immunised rats (green, n = 4, month 16). Columns in (E) depict the fraction of anti-β1EC2-secreting PC 14 days after
antigen-boost (in‰ of IgG-producing cells), in (F) the total amount of IgG-producing cells per 104cells. Error bars represent mean ±SEM in the indicated
groups. (G to J) ELISPOT-assays carried out with bone marrow cells (BM) and splenocytes prepared from immunised untreated (black) vs. β1EC2-CP-
treated rats (green) from the prevention- (G and H, n = 2 vs. 3 rats) and the therapy-study (I and J, n = 3 vs. 3 rats). Columns in (G) and (I) depict the fraction of
anti-β1EC2-secreting cells 3 days after antigen-boost (vs. IgG-producing cells); columns in (H) and (J) show the total amount of IgG-producing cells per
104cells. (K and L) Direct flow cytometric detection of β1EC2-specific B-cells. The numbers in the dot plots indicate percentages per quadrant. (M)
Concentration of anti-β1EC2-IgG in the sera of recipient rats after adoptive transfer of B-cells from donors treated as indicated followed by suboptimal
immunisation with FP in adjuvans. Error bars represent mean ±SEM in the indicated groups (Student’s t-test, *p<0.05).
doi:10.1371/journal.pone.0117589.g005
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stimulating anti-β1EC2 abs cause partial, but chronic activation of cardiomyocyte β1-ARs, and
thus potentiate the vicious circle of sympathetic activation and HF-progression [3,4,6].
Mode of action of β1-receptor mimicking cyclic peptides
In our study, monthly injections of β1EC2-CP either prevented (preventive application) or even
reversed (therapeutic application) the detrimental consequences of stimulating anti-β1EC2.
These injections were tolerated well by both immunised anti-β1EC2-positive rats and anti-
body-naïve control animals, and over one year of treatment did not elicit any apparent β1EC2-
CP-related adverse effects, neither in routine blood laboratory tests nor in a series of organs (S3
and S4 Figs.). In addition, the protection achieved with monthly β1EC2-CP-injections was
clearly superior to daily applications of 15 mg/kg bisoprolol alone, although mono-treatment
with bisoprolol was able to stop the progression of immunisation-induced heart failure. Unlike
bisoprolol, β1EC2-CP mono-treatment affected neither heart rate nor blood pressure. The ben-
eficial effects of β1EC2-CP must at least in part be due to scavenging of anti-β1EC2, as is evi-
dent from the specific and high-affinity recognition of these antibodies which reflects both the
primary sequence of the epitope (by comparison with the β1EC1- or β2EC2-peptides) as well as
the structure (by comparison with the linear β1EC2-peptide). In addition, β1EC2-CP had a
long half-life in blood, which contributes to its scavenging-efficacy.
In addition to its anti-β1EC2-neutralizing action, the most intriguing effect of β1EC2-CP
was the ability to essentially block further anti-β1EC2 antibody-production despite continuous
antigen-boosts. As detailed in the results-section this failure to respond to the antigen boosts is
due to depletion or functional inactivation of β1EC2-specific memory B-cells. On a molecular
level this depletion is explained by monomeric, e.g. non-productive, stimulation of the BCR
[42] precluding an expansion of anti-β1EC2-expressing memory B-cells in β1EC2-CP
-treated animals.
As in the case of direct scavenging, the effect on anti-β1EC2-expressing memory B-cells was
sequence- and epitope-specific, and was, in particular, not elicited by the corresponding linear
peptide (S2 and S5 Figs.).
While direct targeting of PC in anti-β1EC2-mediated HF remains a challenge, the cyclo-
peptide-approach presented here neutralises the products of short-lived plasmablasts as well as
long-lived PC (i.e. existing anti-β1EC2-antibodies) and hits β1EC2-specific memory B-cells. Al-
though antibody-neutralisation appears sufficient to mediate protection in this model, we
hypothesise that depletion of the β1EC2-specific memory B-cells may be important for main-
taining low antibody-titers and, therefore, enhances the long-term therapeutic efficacy of our
approach. By this double action β1EC2-CPs not only prevent antibody-induced β1-AR activa-
tion, but also address the site of antibody-generation, and thereby prevent or revert anti-
β1EC2-induced cardiac damage. These positive effects were seen in terms of cardiac morpholo-
gy and function as well as different microscopic, laboratory, and molecular parameters. More-
over, in β1EC2-CP-treated animals, together with the restauration of cardiac membrane β1-AR,
also the increases in GRK2- and GRK5-expression were almost fully reverted. These effects
were even more pronounced, when injecting β1EC2-CP (as an add-on) to bisoprolol-treatment,
resulting in a slight (non-significant) downregulation of both GRK’s. This is of particular inter-
est, as increases in cardiac GRK-transcripts are thought to represent an early adaptation to ad-
renergic stress preceding β1-AR desensitisation [4,43,44]. In addition, increases in cardiac
GRK-transcripts have been shown to correlate well with disease severity in HF patients [44],
suggesting that β1EC2-CP treatment alone or—on a molecular level even more efficient—com-
bined with a β1-receptor blocking agent (which corresponds better to the current clinical
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requirements and treatment guidelines) might also act beneficially in anti-β1EC2-mediated
human heart failure.
Chronic heart failure, relevance of the immune system, and new
therapeutic strategies
Various factors may contribute to non-ischaemic DCM, including persistent viral infection
[45] and autoimmune-mediated damage to myocytes [46,47,48]. These factors may coincide,
because autoimmune-reactions to myocardial proteins may be virus-triggered [31,47]. In the
last decade a growing number of heart-directed abs and alterations of the immune system have
been described in heterogeneous subsets of patients with DCM [34,46,49], indicating that mul-
tiple mechanisms may play a role in the pathogenesis of autoimmune-mediated heart failure
(HF). Amongst others, abnormalities have been found in cytokines [46], T lymphocyte subsets,
and in cells mediating myocardial inflammation [50]. Moreover, in>30% of DCM patients
abnormal immune-reactions against distinct cardiac self-antigens have been described, includ-
ing autoantibodies against myocyte contractile proteins [47,51], mitochondrial proteins [52],
and membrane receptors [10,53,54]. However, only a few of them have been shown to cause,
in fact, myocardial tissue injury and congestive HF by themselves [18,35,51]. In humans the
individual genetic predisposition also significantly influences the susceptibility to self-directed
immune-reactions [34,49,55], but the so far available clinical data underscore the pathophysio-
logical and clinical importance of stimulating anti-β1AR-abs in HF and the need for novel anti-
body-directed therapeutic strategies [6,36,56]. We demonstrate here that anti-β1EC2-mediated
cardiostimulatory effects in vivo cannot be efficiently neutralised with β1-receptor blockers
alone. This finding fits perfectly with in vitro data using anti-β1EC2 isolated from DCM-pa-
tients [8]. Other experimental antibody-directed strategies consist in their removal from the
blood by immunoadsorption [36,57,58] or, more recently, in the development of anti-β1AR-
neutralising small oligonucleotides currently assayed in vitro [56].
As a simple alternative, we present here a novel specific and very efficient strategy to treat
autoimmune-mediated HF in vivo with cyclopeptides mimicking the target-domain of stimu-
lating anti-β1EC2-antibodies (administered alone or as an add-on to β1-receptor blocker treat-
ment). β1EC2-CPs acted as antibody-scavengers in the circulation, but also depleted or
functionally inhibited anti-β1EC2-expressing memory B-cells involved in antibody-production.
Our data suggest that β1EC2-CPs (alone or combined with a β1-receptor blocking drug) might
evolve into a novel save and efficient strategy to neutralise stimulating anti-β1EC2 also in
human HF. Furthermore, it will be interesting to investigate whether such cyclic peptides
might prove to be beneficial also in other autoantibody-mediated diseases.
Conclusions
By taking advantage of a human-analogous rat model the here presented in vivo-experiments
provide the basis for the clinical translation of a novel double-acting therapeutic strategy for
immune-mediated heart failure. Cyclic peptides mimicking the target epitope of functionally
active antibodies stimulating the cardiac β1-adrenergic receptor on the one hand act as direct
antibody-scavengers in the circulation thereby precluding antibody-induced harm from the
heart; in addition, the cyclic peptides were found to have a long-term effect by selectively de-
pleting memory B-cells involved in the production of cardio-noxious receptor antibodies. Be-
sides the prevention and/or treatment of immune heart failure (either as a mono-substance or
combined with a β1-receptor blocking agent) the here presented approach might be helpful
also in other autoantibody-mediated diseases.
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Supporting Information
S1 Fig. Effect of different peptides on anti-β1EC2-antibody titres (therapy-study). Time
course of anti-β1EC2-titers in the therapy study measured before and 24h afterCP-injections. Ab-
solute antibody-concentrations over 20 study-months are shown (mg/ml; black circles, untreated;
green diamonds: β1EC2-CP (1.0 mg/kg/month i.v.); blue triangles: bisoprolol (15 mg/kg/day oral-
ly); grey squares: β1EC2-Lin (1.0 mg/kg/month i.v.); green squares: β1EC1-Lin (1.0 mg/kg/month
i.v.)); for better readability error-bars are not shown in the graph.
(TIF)
S2 Fig. Effect of different peptides on various echocardiographic and haemodynamic pa-
rameters in the prevention- and the therapy-study. Echocardiographic follow-up in the (A,
C) prevention- and (B,D) therapy-study. Graphs (A) and (B) show the time-course of LV end-
diastolic and end-systolic diameters (LVED, LVES), graphs (C) and (D) the cardiac index (de-
rived from cardiac output/body weight) in the prevention- and the therapy-arm of the study,
respectively. Error bars indicate mean ±SEM; p<0.01, p<0.001, p<0.0001 (two way
ANOVA and Bonferroni post-hoc test). Invasively obtained haemodynamic parameters in the
(E) prevention- and (F) therapy-study. Panels (from top to bottom) show heart frequence
(bpm), maximal systolic LV-pressure (mmHg), LV end-diastolic pressure (mmHg), LV-contrac-
tility (+dP/dt, mmHg/s), and -relaxation (-dP/dt, -mmHg/s). Error bars indicate mean ±SEM;
p<0.01; p<0.001, p<0.0001 (one way ANOVA and Dunnett`s post-hoc test).
(TIF)
S3 Fig. Histologic analysis of various organs (therapy-study, mono-treatment). Representa-
tive H&E-stained 2μm cross-sections from various organs analyzed for treatment-related pa-
thologies. Panels (from top to bottom) show organs analyzed from immunised anti-β1EC2-
positive untreated, β1EC2-CP-treated, or bisoprolol-treated rats. Representative sections from
brain, liver, heart, kidney, eye, and spleen after 12 months of treatment are demonstrated. Nei-
ther treatment strategy caused detectable organ-specific toxicity or therapy-related pathologies.
(TIF)
S4 Fig. Routine laboratory parameters (therapy-study, mono-treatment). Columns ± error
bars represent the mean values ±SEM for different laboratory serum parameters in the indicated
treatment groups (from left to right, top row: AST, aspartate-aminotransferase; ALT, alanine-
aminotransferase; aP, alkaline phosphatase; Crea, creatinine; Urea, urea. Bottom row: GGT,
gamma-glutamyltransferase; GLDH, glutamat lactate dehydrogenase; Bili, bilirubin; Myo, myo-
globin; CK, creatinine kinase); p<0.05 (one way ANOVA and Dunnett`s post-hoc test).
(TIF)
S5 Fig. Effect of cyclic versus linear peptides on splenocytes. ELISPOT-assays carried out
with bone marrow cells (BM) and splenocytes prepared from immunised untreated (black, n =
3) vs. β1EC2-CP-treated (dark green, n = 5) vs. β1EC2-Lin-treated animals (light green, n = 3).
Columns in (A) depict the fraction of anti-β1EC2-secreting cells 3 days after antigen-boost (in‰
of IgG-producing cells); columns in (B) show the total amount of IgG-producing cells per
104cells. Error bars indicate mean ±SEM; p<0.05 (one way ANOVA and Dunnett`s post-hoc
test).
(TIF)
Acknowledgments
We are deeply indebted to Sandra Werner and Christina Zechmeister for excellent technical as-
sistance. Bisoprolol was kindly donated from BAYER Health Care Inc., Düsseldorf, Germany.
Cyclopeptide-Therapy in Immune Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0117589 February 20, 2015 20 / 24
Author Contributions
Conceived and designed the experiments: VB NB DP VON AS VK TK GEMJL RJ. Performed
the experiments: VB NB DP VON AS JM DS VK RJ. Analyzed the data: VB NB DP VON AS
JM DS VK TK TH GEMJL RJ. Contributed reagents/materials/analysis tools: NB DP VON AS
JM TK THMJL. Wrote the paper: VB NB VON AS JM VK TK TH GEMJL RJ.
References
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis
and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Devel-
oped in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the Europe-
an Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388–2442. doi: 10.1093/eurheartj/
ehn309 PMID: 18799522
2. Störk S, Boivin V, Horf R, Hein L, Lohse MJ, et al. (2006) Stimulating autoantibodies directed against
the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am
Heart J 152: 697–704. PMID: 16996841
3. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, et al. (1984) Plasma norepinephrine as a guide to
prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823. PMID:
6382011
4. Bristow MR (2011) Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a con-
vergence of receptor pharmacology and clinical cardiology. Circ Res 109: 1176–1194. doi: 10.1161/
CIRCRESAHA.111.245092 PMID: 22034480
5. Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart
failure? Circ Res 93: 896–906. PMID: 14615493
6. Freedman NJ, Lefkowitz RJ (2004) Anti-beta1-adrenergic receptor antibodies and heart failure: causa-
tion, not just correlation. J Clin Invest 113: 1379–1382. PMID: 15146232
7. Hébert TE (2007) Anti-beta1-AR antibodies in dilated cardiomyopathy: are these a new class of recep-
tor agonists? Cardiovasc Res 76: 5–7. PMID: 17707357
8. Nikolaev VO, Boivin V, Stork S, Angermann CE, Ertl G, et al. (2007) A novel fluorescence method for
the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. Journal of the
American College of Cardiology 50: 423–431. PMID: 17662395
9. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, et al. (2006) Contemporary definitions and
classification of the cardiomyopathies: an American Heart Association Scientific Statement from the
Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Out-
comes Research and Functional Genomics and Translational Biology Interdisciplinary Working
Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807–1816. PMID: 16567565
10. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, et al. (1999) Autoantibodies activating human
beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circu-
lation 99: 649–654. PMID: 9950662
11. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, et al. (2001) Autoantibodies against the second
extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in pa-
tients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 37: 418–424. PMID: 11216956
12. Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, et al. (2000) Modulation of beta1-adrenoceptor activi-
ty by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol 36:
1280–1287. PMID: 11028484
13. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, et al. (2008) Structure of a
beta1-adrenergic G-protein-coupled receptor. Nature 454: 486–491. doi: 10.1038/nature07101 PMID:
18594507
14. Magnusson Y, Hoyer S, Lengagne R, Chapot MP, Guillet JG, et al. (1989) Antigenic analysis of the sec-
ond extracellular loop of the human beta-adrenergic receptors. Clin Exp Immunol 78: 42–48. PMID:
2478327
15. Hoebeke J (1996) Structural basis of autoimmunity against G protein-coupled membrane receptors. Int
J Cardiol 54: 103–111. PMID: 8803673
16. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. (2007) High resolution
crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:
1258–1265. PMID: 17962520
Cyclopeptide-Therapy in Immune Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0117589 February 20, 2015 21 / 24
17. Bornholz B, Weidtkamp-Peters S, Schmitmeier S, Seidel CAM, Herda LR, et al. (2013) Impact of
human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardio-
vasc Res: 472–480. doi: 10.1093/cvr/cvt206 PMID: 23975852
18. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, et al. (2004) Direct evidence for a beta 1-adrener-
gic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest
113: 1419–1429. PMID: 15146239
19. Ireland DC, Colgrave ML, Nguyencong P, Daly NL, Craik DJ (2006) Discovery and characterization of a
linear cyclotide from Viola odorata: implications for the processing of circular proteins. J Mol Biol 357:
1522–1535. PMID: 16488428
20. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, et al. (1987) Cloning of the cDNA for the
human beta1-adrenergic receptor. Proc Natl Acad Sci USA 84: 7920–7924. PMID: 2825170
21. Jahns R, Siegmund C, Jahns V, Reiländer H, Maidhof A, et al. (1996) Probing human beta1- and
beta2-adrenoceptors with domain-specific fusion protein antibodies. Eur J Pharmacol 316: 111–121.
PMID: 8982658
22. Litwin SE, Katz SE, Morgan JP, Douglas PS (1994) Serial echocardiographic assessment of left ven-
tricular geometry and function after large myocardial infarction in the rat. Circulation 89: 345–354.
PMID: 8281668
23. Bristow MR (1993) Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol
22: 61A–71A. PMID: 8397233
24. Ungerer M, Parruti G, BöhmM, Puzicha M, De BA, et al. (1994) Expression of b-arrestins and β-adren-
ergic receptor kinases in the failing human heart. Circ Res 74: 206–213. PMID: 8293560
25. Martini JS, Raake P, Vinge LE, DeGeorge BR Jr., Chuprun JK, et al. (2008) Uncovering G protein-cou-
pled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl
Acad Sci U S A 105: 12457–12462. doi: 10.1073/pnas.0803153105 PMID: 18711143
26. Thorstenson KM, Khoruts A (2001) Generation of anergic and potentially immunoregulatory
CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J
Immunol 167: 188–195. PMID: 11418648
27. Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specific therapy of murine lupus nephritis
using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B
cells. J Immunol 162: 5775–5783. PMID: 10229810
28. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A (1998) Survival of long-lived plasma cells is in-
dependent of antigen. Int Immunol 10: 1703–1711. PMID: 9846699
29. Savelyeva N, King CA, Vitetta ES, Stevenson FK (2005) Inhibition of a vaccine-induced anti-tumor B
cell response by soluble protein antigen in the absence of continuing T cell help. Proc Natl Acad Sci U
S A 102: 10987–10992. PMID: 16037207
30. Naparstek Y, Plotz PH (1993) The role of autoantibodies in autoimmune disease. Annu Rev Immunol
11: 79–104. PMID: 8476578
31. Rose NR (2001) Infection, mimics, and autoimmune disease. J Clin Invest 107: 943–944. PMID:
11306595
32. Endo K, Kasagi K, Konishi J, Ikekubo K, Okonu T, et al. (1978) Detection and properties of TSH-binding
inhibitorimmunoglobulins in patients with Grave's disease and Hashimoto's thyroiditis. J Endocrinol
Metab 46: 734–739. PMID: 45421
33. Tzartos SJ, Seybold ME, Lindstrom JM (1982) Specificities of antibodies to acetylcholine receptors in
sera frommyasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA
79: 178–192.
34. Limas CJ, Iakovis P, Anyfantakis A, Kroupis C, Cokkinos DV (2004) Familial clustering of autoimmune
diseases in patients with dilated cardiomyopathy. Am J Cardiol 93: 1189–1191. PMID: 15110223
35. Jane-wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, et al. (2007) Beta1-adrenergic receptor au-
toantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circu-
lation 116: 1–12. PMID: 16824626
36. Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoadsorption. Ann
NY Acad Sci 1051: 635–646. PMID: 16127004
37. Hoyer PF, Vester U (2004) The impact of cyclosporine on the development of immunosuppressive ther-
apy—pediatric transplantation using cyclosporine. Transplant Proc 36: 197S–202S. PMID: 15041336
38. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune dis-
eases. Nat Rev Immunol 6: 394–403. PMID: 16622478
Cyclopeptide-Therapy in Immune Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0117589 February 20, 2015 22 / 24
39. Neubert K, Meister S, Moser K, Weisel F, Maseda D, et al. (2008) The proteasome inhibitor bortezemib
depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748–755.
doi: 10.1038/nm1763 PMID: 18542049
40. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, et al. (2007) Unexpected cardiotoxicity in haematolo-
gical bortezomib treated patients. Br J Haematol 138: 396–397. PMID: 17561972
41. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, et al. (2001) Autoimmunity against the second ex-
tracellular loop of beta1-adrenergic receptors induces beta-adrenergic receptor desensitization and
myocardial hypertrophy in vivo. Circ Res 88: 578–586. PMID: 11282891
42. Kim YM, Pan JY, Korbel GA, Peperzak V, Boes M, et al. (2006) Monovalent ligation of the B cell recep-
tor induces receptor activation but fails to promote antigen presentation. Proc Natl Acad Sci U S A 103:
3327–3332. PMID: 16492756
43. Ungerer M, BöhmM, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of β-adrenergic recep-
tor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87: 454–463. PMID:
8381058
44. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, et al. (2006) Mechanisms of regulation of G protein-
coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovascular Research 69: 46–56.
PMID: 16288730
45. Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, et al. (2005) Viral persistence in the myo-
cardium is associated with progressive cardiac dysfunction. Circulation 112: 1965–1970. PMID:
16172268
46. Luppi P, Rudert WA, Zanone MM, Stassi G, Trucco G, et al. (1998) Idiopathic dilated cardiomyopathy.
A superantigen-driven autoimmune disease. Circulation 98: 777–785. PMID: 9727548
47. Caforio AL, Mahon NJ, Tona F, McKennaWJ (2002) Circulating cardiac autoantibodies in dilated car-
diomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 4: 411–417.
PMID: 12167378
48. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, et al. (2003) Dendritic cell-induced autoimmune
heart failure requires cooperation between adaptive and innate immunity. Nat Med 9: 1484–1490.
PMID: 14625544
49. Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, et al. (2007) Prospective familial assessment in
dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic rela-
tives. Circulation 115: 76–83. PMID: 17179019
50. Noutsias M, Rohde M, Goldner K, Block A, Blunert K, et al. (2011) Expression of functional T-cell mark-
ers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute
myocarditis and dilated cardiomyopathy. Eur J Heart Fail 13: 611–618. doi: 10.1093/eurjhf/hfr014
PMID: 21422001
51. Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, et al. (2006) Cardiac troponin I but not cardiac
troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114: 1693–1702.
PMID: 17015788
52. Schulze K, Becker BF, Schauer R, Schultheiss HP (1990) Antibodies to ADP-ATP carrier—an autoanti-
gen in myocarditis and dilated cardiomyopathy- impair cardiac function. Circulation 81: 959–969.
PMID: 2155073
53. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J (1994) Autoimmunity in idiopathic
dilated cardiomyopathy. Characterization of antibodies against the beta1-adrenoceptor with positive
chronotropic effect. Circulation 89: 2760–2767. PMID: 8205690
54. Fu LXM, Magnusson Y, Bergh CH, Waagstein F, Hjalmarson Å, et al. (1993) Localization of a functional
autoimmune epitope on the second extracellular loop of the human muscarinic acetylcholine receptor 2
in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91: 1964–1968. PMID: 7683693
55. MacLellan WR, Lusis AJ (2003) Dilated cardiomyopathy: learning to live with yourself. Nat Med 9:
1455–1456. PMID: 14647516
56. Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I (2011) Aptamer neutralization of beta1-adre-
noceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 109: 986–992. doi: 10.
1161/CIRCRESAHA.111.253849 PMID: 21868696
57. Wallukat G, Müller J, Hetzer R (2002) Specific removal of beta1-adrenergic antibodies directed against
cardiac proteins from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347: 1806. PMID:
12456865
58. Staudt A, Hummel A, Ruppert J, Dörr M, Trimpert C, et al. (2006) Immunoadsorption in dilated cardio-
myopathy: 6-month results from a randomized study. Am Heart J 152: 712e711–712e716. PMID:
16996843
Cyclopeptide-Therapy in Immune Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0117589 February 20, 2015 23 / 24
59. Kaiser E, Colescott RL, Bossinger CD, Cook PI (1970) Color test for detection of free terminal amino
groups in the solid-phase synthesis of peptides. Anal Biochem 34: 595–598. PMID: 5443684
60. Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, et al. (2003) Treatment and
prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal anti-
bodies. J Neuroimmunol 140: 143–152. PMID: 12864982
Cyclopeptide-Therapy in Immune Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0117589 February 20, 2015 24 / 24
